^
    Back
    Association details:
    Biomarker:CD20 positive
    Cancer:Non-Hodgkin’s Lymphoma
    Drug:Rituxan (rituximab) (CD20 inhibitor) +
    utomilumab (PF-05082566) (CD137 agonist)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: C3 – Early Trials
    Source:
    Clin Cancer Res
    Title:

    First-in-Human Study of Utomilumab, a 4-1BB/CD137 Agonist, in Combination with Rituximab in Patients with Follicular and Other CD20+ Non-Hodgkin Lymphomas

    Published date:
    06/01/2020
    Excerpt:
    The objective response rate was 21.2% (95% CI, 12.1%–33.0%) in all patients with NHL, including four complete and 10 partial responses….Utomilumab in combination with rituximab demonstrated clinical activity and a favorable safety profile in patients with CD20+ NHLs.
    DOI:
    10.1158/1078-0432.CCR-19-2973
    Trial ID:
    NCT01307267